Jury Hands AstraZeneca Win In Nexium Pay-For-Delay Case
Law360, New York (December 5, 2014, 2:29 PM EST) -- A Massachusetts federal jury sided with defendants AstraZeneca PLC and Ranbaxy Inc. in the first pay-for-delay class action trial since the U.S. Supreme Court agreed the patent settlements could face antitrust scrutiny, finding that AstraZeneca would never have allowed a generic Nexium to launch before its medicine patents expired.
After a six-week trial and less than two days of deliberations, an 11-person jury rejected claims made by two groups of Nexium buyers that AstraZeneca's Hatch Waxman Act settlement with Ranbaxy Inc. harmed competition. The plaintiffs had argued that AstraZeneca sought to hold on to billions of dollars in profits on Nexium...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!